Focus: Cantata Bio is a biotechnology company specializing in multi-dimensional NGS (next-generation sequencing) technologies focused on oncology applications. Founded in 2013 and headquartered in Scotts Valley, CA, the company operates as a pre-revenue or early-stage biotech with limited public market presence.
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Cantata Bio is a niche, scientifically credible early-stage play in oncology NGS with narrow hiring and opaque financials—suitable only for founders-minded scientists or operators seeking equity upside with high risk tolerance.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Cantata Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Cantata Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
A complete human pancreatic cancer genome.
Improved, annotated reference genome for the highly polyphagous moth Hyphantria cunea (Fall webworm).
Transcriptional rewiring by enhancer methylation in CBFA2T3-GLIS2-driven pediatric acute megakaryoblastic leukemia.
CTCF Mediates the Cis-Regulatory Hubs in Mouse Hearts.
Correction: Development and extensive sequencing of a broadly-consented Genome in a Bottle matched tumor-normal pair.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo